Understanding a Protein Called SETDB1 in Lung Cancer
Dissecting the Mechanism of SETDB1 and its K867 Monoubiquitination in Lung Cancer Progression
This research explores how a protein named SETDB1 contributes to lung cancer growth, especially in patients with certain genetic changes, to find new ways to treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11141731 on NIH RePORTER |
What this research studies
Non-small cell lung cancer (NSCLC) is a serious illness, and while some targeted treatments exist, options for tumors with common KRAS mutations are still limited. This project focuses on a protein called SETDB1, which is often found in higher amounts in many cancers, including NSCLC, and seems to help tumors grow. We want to understand exactly how SETDB1 works in lung cancer cells and how a specific modification to it, called K867 monoubiquitination, affects its function. By uncovering these details, we hope to identify new weaknesses in lung cancer that could lead to more effective treatments, particularly for those with KRAS mutations.
Who could benefit from this research
Good fit: This foundational research is for patients with non-small cell lung cancer, particularly those with KRAS mutations, who may benefit from future targeted therapies developed from these findings.
Not a fit: Patients without non-small cell lung cancer or those whose cancer does not involve the specific mechanisms being studied may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new drug targets and treatment strategies for non-small cell lung cancer, especially for patients whose tumors have KRAS mutations.
How similar studies have performed: While targeted therapies for other lung cancer mutations have shown success, understanding the specific role of SETDB1 and its modifications in KRAS mutant NSCLC represents a novel and less explored area.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Fang, Jia — Roswell Park Cancer Institute Corp
- Study coordinator: Fang, Jia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.